awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q42318760-31EABAC9-7E9F-4152-9BFA-F6E28088CD46
Q42318760-31EABAC9-7E9F-4152-9BFA-F6E28088CD46
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42318760-31EABAC9-7E9F-4152-9BFA-F6E28088CD46
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
P2860
Q42318760-31EABAC9-7E9F-4152-9BFA-F6E28088CD46
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42318760-31EABAC9-7E9F-4152-9BFA-F6E28088CD46
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
591d1900b5b327fa986fbc749b85dbcd7b4127de
P2860
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms